The Schistosomiasis Clinical Trials Landscape: A Systematic Review of Antischistosomal Treatment Efficacy Studies and a Case for Sharing Individual Participant-Level Data (IPD)

Background Schistosomiasis control mainly relies on preventive chemotherapy with praziquantel (PZQ) distributed through mass drug administration. With a target of 260 million treatments yearly, reliably assessing and monitoring efficacy is all-important. Recommendations for treatment and control of schistosomiasis are supported by systematic reviews and meta-analyses of aggregated data, which however also point to limitations due to heterogeneity in trial design, analyses and reporting. Some such limitations could be corrected through access to individual participant-level data (IPD), which facilitates standardised analyses. Methodology A systematic literature review was conducted to identify antischistosomal drug efficacy studies performed since 2000; including electronic searches of the Cochrane Infectious Diseases Group specialised register and the Cochrane Library, PubMed, CENTRAL and Embase; complemented with a manual search for articles listed in past reviews. Antischistosomal treatment studies with assessment of outcome within 60 days post-treatment were eligible. Meta-data, i.e. study-level characteristics (Schistosoma species, number of patients, drug administered, country, etc.) and efficacy parameters were extracted from published documents to evaluate the scope of an individual-level data sharing platform. Principal findings Out of 914 documents screened, 90 studies from 26 countries were included, enrolling 20,517 participants infected with Schistosoma spp. and treated with different PZQ regimens or other drugs. Methodologies varied in terms of diagnostic approaches (number of samples and test repeats), time of outcome assessment, and outcome measure (cure rate or egg reduction rate, as an arithmetic or geometric mean), making direct comparison of published data difficult. Conclusions This review describes the landscape of schistosomiasis clinical research. The volume of data and the methodological and reporting heterogeneity identified all indicate that there is scope for an individual participant-level database, to allow for standardised analyses.

[1]  R. N. Incani,et al.  The efficacy of human schistosomicide treatment may depend on the rate of transmission , 2006, Parasitology Research.

[2]  J. Utzinger,et al.  Toward Measuring Schistosoma Response to Praziquantel Treatment with Appropriate Descriptors of Egg Excretion , 2015, PLoS neglected tropical diseases.

[3]  Schistosomiasis: number of people treated worldwide in 2013. , 2015, Releve epidemiologique hebdomadaire.

[4]  B. Lo.  Sharing clinical trial data: maximizing benefits, minimizing risk. , 2015, JAMA.

[5]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[6]  C. AbouZahr,et al.  Sharing health data: good intentions are not enough. , 2010, Bulletin of the World Health Organization.

[7]  Jürg Utzinger,et al.  Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis , 2008, Current opinion in infectious diseases.

[8]  Q. Zeng,et al.  [Analysis on morbidity and chemotherapy effects of Schistosoma japonicum infection in fishermen on Dongting Lake]. , 2004, Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases.

[9]  P. Andrews.  A summary of the efficacy of praziquantel against schistosomes in animal experiments and notes on its mode of action. , 1981, Arzneimittel-Forschung.

[10]  E. Loker.  A comparative study of the life-histories of mammalian schistosomes , 1983, Parasitology.

[11]  Deborah H. Charbonneau,et al.  Doody's Core Titles in the Health Sciences (DCT) , 2005 .

[12]  Joachim Hübener,et al.  Open Data! , 2012, EnviroInfo.

[13]  R. Riley,et al.  Meta-analysis of individual participant data: rationale, conduct, and reporting , 2010, BMJ : British Medical Journal.

[14]  Florence Debarre,et al.  The Availability of Research Data Declines Rapidly with Article Age , 2013, Current Biology.

[15]  J. Crump,et al.  Evaluation of In-Hospital Management for Febrile Illness in Northern Tanzania before and after 2010 World Health Organization Guidelines for the Treatment of Malaria , 2014, PloS one.

[16]  L. Stewart,et al.  To IPD or not to IPD? , 2002, Evaluation & the health professions.

[17]  D. Moher,et al.  Reprint--preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2009, Physical therapy.

[18]  Belen Pedrique,et al.  The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment. , 2013, The Lancet. Global health.

[19]  A. Swan,et al.  To share or not to share: Publication and quality assurance of research data outputs. A report commissioned by the Research Information Network , 2008 .

[20]  A. Montresor.  Cure rate is not a valid indicator for assessing drug efficacy and impact of preventive chemotherapy interventions against schistosomiasis and soil-transmitted helminthiasis. , 2011, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[21]  J. Zwang,et al.  Clinical Efficacy and Tolerability of Praziquantel for Intestinal and Urinary Schistosomiasis—A Meta-analysis of Comparative and Non-comparative Clinical Trials , 2014, PLoS neglected tropical diseases.

[22]  P. Garner,et al.  Treatment of urinary schistosomiasis: methodological issues and research needs identified through a Cochrane systematic review , 2009, Parasitology.

[23]  R. Gönnert,et al.  Praziquantel, a new broad-spectrum antischistosomal agent , 1977, Zeitschrift für Parasitenkunde.

[24]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[25]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[26]  J. Utzinger,et al.  New approaches to measuring anthelminthic drug efficacy: parasitological responses of childhood schistosome infections to treatment with praziquantel , 2016, Parasites & Vectors.